Meningioma Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - AstraZeneca, Arno Therapeutics, Merck Pharmaceuticals

DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Download Sample Report to know more @ https://www.delveinsight.com/sample-request/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Meningioma Overview
Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the brain and spinal cord.
Symptoms depend on the location and occur as a result of the tumor pressing on nearby tissue. Many cases never produce symptoms. Occasionally seizures, dementia, trouble talking, vision problems, one-sided weakness, or loss of bladder control may occur.
Risk factors include exposure to ionizing radiation such as during radiation therapy, a family history of the condition, and neurofibromatosis type 2. They appear to be able to form from a number of different types of cells including arachnoid cells. Diagnosis is typically by medical imaging.
If there are no symptoms, periodic observation may be all that is required. Most cases that result in symptoms can be cured by surgery. Following complete removal fewer than 20% recur. If surgery is not possible or the tumor cannot be removed, radiosurgery may be helpful. Chemotherapy has not been found to be useful. A small percentage grows rapidly and is associated with worse outcomes.

Click here to learn more about the Meningioma Market Landscape @https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlights from Meningioma Market Report
Meningiomas are the most common primary brain tumors accounting for 33.8--36.8% of primary central nervous system (CNS) tumors. Most are benign encapsulated CNS tumors. Intracranial hemorrhage associated with meningioma is rare.
The prevalence of meningioma is estimated to be 97.5 cases per 100,000 individuals in the United States. There are over 170,000 diagnosed cases in the United States.

Meningioma Treatment Market
Surgery is often the first-line treatment option for meningioma. There are several different techniques that may be used depending on the tumor location. Radiation therapy may be required in cases where there is some tumor tissue left behind following surgery.
Hydroxyurea, a medication that slows or stops the growth of cancer cells, may also be effective for some people with meningioma. Medications that prevent the hormone progesterone from attaching to meningioma cells may also be promising. Some tumors grow when they are exposed to progesterone.

Learn more about the treatment market for Meningioma @ https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Meningioma Epidemiology Segmented by:
Meningioma prevalent cases
Meningioma Incident Cases
Meningioma treatment cases
Meningioma diagnosed cases

Meningioma Dug Profile and Companies Covered
Arno Therapeutics Inc : Nivolumab
AstraZeneca Plc : Everolimus
Boehringer Ingelheim GmbH : Cabozantinib
Eli Lilly and Co : Abemaciclib
Genentech Inc : Mifepristone
GlaxoSmithKline Plc : AZD2014
Merck : Lutathera
Novartis AG : SOM230C
Ono Pharmaceutical Co Ltd-Ipilimumab
And many others.

Learn more about the Key Companies and Emerging Therapies in the Meningioma Market @https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Meningioma Introduction
Executive Summary of Meningioma
Disease Background and Overview
Meningioma Epidemiology and patient population
Meningioma Emerging Therapies
Meningioma Market Outlook
Meningioma Market Access and Reimbursement of Therapies
Meningioma Market Drivers
Meningioma Market Barriers
Appendix
Meningioma Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Meningioma Market Outlook report @ https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Meningioma Epidemiology Forecast
https://www.delveinsight.com/report-store/meningioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Meningioma Pipeline Forecast
https://www.delveinsight.com/report-store/meningioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.